29.3 C
Vientiane
Friday, May 16, 2025
spot_img
Home Blog Page 369

Crazy Domains Launches the ‘It’s AUstralian for BIG Ideas’ .au Direct Campaign – Creating Awareness of the Power of a Local Online Presence with a .au Domain Name

SYDNEY, April 2, 2025 /PRNewswire/ — Crazy Domains, an Australian leader in domain registration and online solutions, is launching a campaign supported by the .au Domain Administration (auDA), the organisation responsible for administering the AU family of domain names, relied on by internet users in Australia and around the world. The campaign aims to create awareness about what businesses need in today’s world to succeed online.

At the heart of the campaign is the message: “It’s AUstralian for BIG ideas”, which emphasizes the pain points businesses face today. Through a light-hearted four-part video series, the campaign highlights how modern solutions are available to address these needs. Crazy Domains aims to empower even the smallest businesses to move beyond personal email accounts, reliance on social media alone, and the uncertainty of where to begin their online journey. It’s about standing out, building credibility, and leveraging the right tools to compete in an increasingly global marketplace.

The campaign aims to reshape the perception of .au Domain Names by highlighting the following:

  • The Importance of Local Domain Names – Showcasing how a .au Direct is easy to remember, uniquely Australian, and enhances brand identity for a strong and trusted online presence. auDA’s research has shown that 50% of Australian consumers surveyed say they only shop on websites ending in .au – speaking to the levels of consumer confidence in .au domain names.
  • Easy Tools to Get Your Website Live in Minutes – Demonstrating how SMBs as complete beginners can effortlessly launch a website in minutes using Crazy Domains’ AI-powered Website Builder. Every .au Direct purchase comes with a 90-day website builder trial.
  • An Email That Means Business – Highlighting the value of a professional branded business email that increases your authenticity and credibility of your business and communication in a world where online scams and threats are growing by the day. Every .au Direct purchase comes with a 30-day business e-mail hosting trial.
  • An Online Presence is Vital for Small Businesses – Emphasizing the necessity of an online presence in today’s digital world where Australians rely on the internet to products, services and information. A social media presence is great for brand awareness, but auDA research shows that 3 in 4 Australian consumers will only purchase from a business online if it has a website.

“Our mission is simple – to make it easy for Aussie businesses to succeed online,” says Hendrik Kruizinga, Vice President APAC at Crazy Domains. “Supported by auDA’s Co-Marketing Program, we’re not only helping Aussie businesses get online but also ensuring they have the right tools to grow and scale with a .au Direct Domain Name.”

This campaign underscores the power of local branding and the importance of having a strong, professional online identity. Crazy Domains invites all aspiring and established businesses to seize this opportunity and start their online journey today.

For more information about the campaign, visit crazydomains.au.

About Crazy Domains  

Crazy Domains was established in the year 2007. From humble beginnings, we’ve grown to become the #1 Online Solutions Provider in Australia, New Zealand, Singapore, and Southeast Asia, reaching across the United Kingdom and India. Our solutions include domains, cloud web hosting, email hosting, online marketing services, web and logo design, and more—all with the goal of helping our customers thrive online. We assist entrepreneurs, SMBs, and larger, established businesses go from good to legendary. 

About Newfold Digital

Newfold Digital is a leading web and commerce technology company serving nearly 7 million customers globally. Established in 2021 through the combination of leading web services providers Endurance Web Presence and Web.com Group, our portfolio of brands includes: Bluehost, Crazy Domains, HostGator, Network Solutions, Register.com, Web.com, Yoast, YITH, and many others. We help customers of all sizes build a digital presence that delivers results. With our extensive product offerings and personalized support, we take pride in collaborating with our customers to serve their online presence needs. Learn more about Newfold Digital at Newfold.com.

Media Contact

Paola Lorenzo, Public Relations Manager at Newfold Digital
corporatecommunications@newfold.com

Logo – https://laotiantimes.com/wp-content/uploads/2025/04/crazy_domains_logo.jpg

Leadership Meets the Future: AI Coaching Assistant Unveiled at Uncommon Leadership Academy Showcase in Singapore

SINGAPORE, April 2, 2025 /PRNewswire/ — Last week an exclusive group of top executives, HR professionals, and corporate decision-makers gathered at CATAPULT’s Leaders Unleashed Campus in Singapore to experience the next evolution of leadership development—a groundbreaking AI-powered coaching assistant designed to transform how leaders grow, coach, and lead. Initial video summary available here.

Uncommon Leadership Academy Launches Executive AI-Coaching Assistant at CATAPULT's Leaders Unleashed Campus in Singapore March 27, 2025
Uncommon Leadership Academy Launches Executive AI-Coaching Assistant at CATAPULT’s Leaders Unleashed Campus in Singapore March 27, 2025

Hosted by Ruchira Chaudhary, leadership expert and acclaimed author of Coaching: The Secret Code to Uncommon Leadership, this invite-only Uncommon Leadership Academy (ULA) showcase offered a first-of-its-kind, immersive leadership experience, alongside a variety of focused leadership workshops and development tools. The award winning book, listed as required reading at many top flight business schools globally, is now leveraged across new channels and technologies by underpinning the AI training content showcased at the event.

“Coaching is the leadership superpower of the future. Our goal is to enable leaders by giving them the tools to improve themselves, to then elevate their organizations. We all know that organizations with better leaders throughout drive stronger businesses. With AI assistance, we can cascade this power across entire organizations—delivering actionable feedback that drives real behavior change.”

Ruchira Chaudhary
Co-Founder, Uncommon Leadership Academy

In a stunning high-tech setting featuring a 180-degree 8K display, attendees witnessed firsthand how AI-coaching assistants can provide real-time insights, executive coaching strategies, and leadership development support—not as a replacement for human coaches, but as a powerful assistant to enhance executive learning and leadership impact.


“The future of leadership is not just about skills—it’s about coaching, adaptability, and innovation. The Uncommon Leadership Academy is paving the way for a new generation of leader-coaches who don’t just manage but inspire and transform. At CATAPULT, we are honored to host this showcase, where we explore the power of coaching, cutting-edge AI learning tools, and the frameworks that will define the next era of leadership. Having worked with Ruchira for many years, I can say with confidence—her insights and passion for leadership development are second to none.”

 – Dr. James Andrade
Head of CATAPULT Executive Leadership & Innovation Institute

As an addition to Uncommon Leadership Academy’s focused live workshops with Ruchira, supplemental workbooks and Learning Cards, the AI Assisted Coaching represents true innovation in the challenge to develop the next generation of leaders.

END

Exclusive Interview Opportunities

For select top-tier media, Ruchira Chaudhary is available for exclusive, one-on-one interviews on:

  • The Ethics of AI in Leadership Development – Why AI should assist, not replace, human coaching.
  • The Future of Executive Coaching – How AI is making leadership coaching more personalized and effective.
  • Leadership in a Changing World – How businesses, from family enterprises to Fortune 500s, can develop stronger leaders.
  • The Role of AI in Private Equity Leadership Development – How AI coaching can drive leadership growth across PE portfolio companies.

Media Resources & Contact

Full Video & B-Roll Available for press requests
High-resolution event images
Speaker quotes & key takeaways
Exclusive interview opportunities with Ruchira Chaudhary

Media Inquiries: media@uncommon-leadership.com 
+65 9617 7145
uncommon-leadership.com

 

UY SCUTI ACQUISITION CORP. ANNOUNCES CLOSING OF $50 MILLION INITIAL PUBLIC OFFERING

NEW YORK, April 2, 2025 /PRNewswire/ — UY Scuti Acquisition Corp. (NASDAQ: UYSCU), (the “Company”), today announced the closing of its initial public offering of 5,000,000 units at an offering price of $10.00 per unit. Each unit consists of one ordinary share, par value $0.0001 per share, and one right to receive one-fifth (1/5th) of an ordinary share. The units are listed on The NASDAQ Capital Market (“NASDAQ”) and began trading under the ticker symbol “UYSCU” on March 31, 2025. Once the securities comprising the units begin separate trading, the ordinary shares and rights are expected to trade on NASDAQ under the symbols “UYSC”, and “UYSCR”, respectively.

Maxim Group LLC acted as the sole book-running manager for the offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 750,000 units at the initial public offering price to cover over-allotments, if any.

Becker & Poliakoff, P.A. served as legal counsel to the Company and Loeb & Loeb LLP served as legal counsel to Maxim Group LLC in the offering.

A registration statement on Form S-1 relating to these securities (SEC File Number 333-284815) was declared effective by the Securities and Exchange Commission on March 31, 2025. The offering is being made only by means of a prospectus, copies of which may be obtained by contacting Maxim Group LLC, located at 300 Park Avenue, 16th Floor, New York, NY 10022, by email at syndicate@maximgrp.com, or by telephone at +1-212-895-3500.  Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About UY Scuti Acquisition Corp. 

UY Scuti Acquisition Corp. is a newly organized blank check company formed under the laws of the Cayman Islands for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

Forward Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward looking statements are statements that are not historical facts. Such forward-looking statements, including with respect to the Company’s search for an initial business combination, are subject to risks and uncertainties, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the offering filed with the SEC, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based, except as required by law.

Company Contact:

Mr. Shaokang Lu
Chief Financial Officer
UY Scuti Acquisition Corporation
39 E Broadway, Suite 603
New York, NY 10002
Tel: (412) 947-0514
Email: kenlu@uysacquisition.com

Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

MELBOURNE, Australia, April 2, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that a first patient has been dosed in the Phase 1 ZOLAR[1] trial of TLX300-CDx (89Zr-olaratumab) in patients with advanced, metastatic soft tissue sarcoma (STS) at the Melbourne Theranostic Innovation Centre (MTIC) in Melbourne, Australia.

ZOLAR is a first-in-human, proof-of-concept and biodistribution trial that uses positron emission tomography (PET) to evaluate olaratumab, a monoclonal antibody, as a therapeutic radiopharmaceutical targeting platform. Olaratumab targets platelet-derived growth factor receptor alpha (PDGFRα) a cell surface protein often over-expressed in STS.

The aim of the trial is to evaluate the safety, pharmacokinetics, biodistribution and dosimetry, and establish the optimal dose of TLX300-CDx in patients with advanced STS, prior to therapeutic studies, based on a theranostic approach. As part of the study, it is also expected that the patient dosimetry and target expression characteristics will inform the final selection of therapeutic radionuclide for this candidate, in conjunction with currently active non-clinical radiation biology studies.

Telix intends to develop a novel targeted radionuclide therapy, specific for PDGFRα, which could be used to treat patients with STS. Telix holds the exclusive worldwide rights to develop and commercialize radiolabelled forms of olaratumab, which was originally developed by Eli Lilly and Company (Lilly).

Professor Rodney Hicks AM, Founder, Chair, and Chief Medical Officer at MTIC, and Principal ZOLAR Investigator, said, “Sarcomas are individually very rare and they can arise from a variety of different tissues. Unfortunately, they tend to respond rather poorly to chemotherapy. While localized STS generally responds to radiotherapy, it is challenging to treat once it has spread. Targeted radionuclide therapy, which targets cancer cells throughout the body, is therefore an attractive option to treat disseminated disease. At MTIC, we’re fortunate to be the first site validating this investigational agent as a precision diagnostic and to inform the design of future therapeutic studies.”

Dr. David N. Cade, Telix Group Chief Medical Officer, added, “We are pleased that a first patient has been imaged in the first-in-human ZOLAR trial, which is designed to inform both the potential efficacy (dosimetry) and safety profile of this research candidate as a therapeutic, based on a theranostic approach. We would like to thank Professor Hicks and his team at MTIC for their commitment to addressing unmet medical need in STS, as well as the patients who will contribute to this important trial.”

Visit the Telix website to view a short video of Professor Hicks explaining the theranostic approach in soft tissue sarcoma here.

TLX300-CDx has not received a marketing authorization in any jurisdiction.

About Soft Tissue Sarcoma (STS)

Soft tissue sarcoma is a complex disease that encompasses a diverse group of relatively rare cancers, with more than 50 malignant histological subtypes. In the United States (U.S.), it is estimated that there will be approximately 13,520 new diagnoses and 5,420 deaths from STS in 2025, representing 0.66% of overall cancer incidence and 0.88% of overall cancer mortality[2]. Standard treatment for soft tissue sarcoma includes surgery, radiation therapy and/or chemotherapy. For patients with advanced, unresectable, or metastatic disease, treatment typically involves chemotherapy with single agents (e.g., doxorubicin) or anthracycline-based combination regimens. However, the prognosis for these patients remains poor, with treated patients with metastatic disease having a median overall survival of around 12–18 months[3].

About olaratumab

Olaratumab (previously marketed under the brand name, Lartruvo®) was originally developed by Lilly as a monoclonal antibody targeting PDGFRα. Olaratumab was granted “Accelerated Approval” in the U.S. and “Conditional Approval” in the EU based on Phase 2 trial data. Olaratumab was voluntarily withdrawn from the market by Lilly following the failure of the Phase 3 ANNOUNCE clinical trial, in which olaratumab in combination with standard chemotherapy did not improve survival for patients compared to chemotherapy alone.

In April 2022, Telix secured the exclusive worldwide rights to develop and commercialize radiolabelled forms of olaratumab for the diagnosis and treatment of human cancers[4]. Olaratumab has a well-established clinical safety profile and a favorable toxicology dataset, which Telix is leveraging for radiopharmaceutical development.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedInX and Facebook.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.

[1] ClinicalTrials.gov ID: NCT06537596.

[2] American Cancer Society 2025.

[3] In et al. Ther Adv Med Oncol. 2017.

[4] Telix ASX disclosure 11 April 2022.

 

FT. Brahmā Aesthetics Introduces Its US-Developed USFT Color Nourishing Technology to Thailand

The Personalized, Non-invasive Treatment Expands Possibilities for Thai Women as Semi-Permanent Makeup Gains Popularity

TAIPEI, April 1, 2025 /PRNewswire/ — FT. Brahmā Aesthetics is announcing its innovative USFT Color Nourishing Technology is now available in Thailand, offering an advanced, semi-permanent makeup solution that is designed specifically for Asian skin tones. The move is part of the company’s recent expansion to empower individuals globally with access to advanced, high-quality, and non-invasive solutions.

FT. Brahmā Aesthetics
FT. Brahmā Aesthetics

As the semi-permanent makeup industry has advanced and grown significantly worldwide, it has become a game-changer as a needle-free, non-invasive option, addressing skin pigmentation concerns caused by genetics, hormones, aging, and skin tone, such as stretch marks and hyperpigmentation. In Thailand, where there is a high prevalence of breast cancer among women, the treatment has particular potential to help with post-recovery aesthetic restoration.

Color Nourishing Technology: A Painless Skin Pigmentation Solution

USFT Color Nourishing Technology, developed in the United States, is a revolutionary non-invasive, non-tattoo-based treatment. Unlike laser or invasive procedures, this technology delivers a natural pinkish glow without creating open wounds.

The procedure is performed by certified specialists who customize the formula for each client, creating a specialized exfoliation solution that enhances the natural skin regeneration process and reduces melanin production. A single session provides permanent results, requiring only at-home maintenance to sustain long-term effectiveness.

The services offered by FT. Brahmā Aesthetics utilizing this technology include areola lightening, European-style lip embroidery, and intimate area brightening, delivering effective, and long-lasting results.

Sunny: An Expert in Semi-Permanent Makeup & Skin Brightening

Sunny, the visionary behind FT. Brahmā Aesthetics, began her journey in the industry by assisting breast cancer survivors with areola reconstruction. She quickly realized the limitations of traditional tattoo-based techniques in achieving a natural pink tone. Motivated by this gap in the market, she sought out the most advanced solutions, undergoing extensive training in Taiwan, Singapore, Malaysia, China, and Europe.

After discovering the USFT Color Nourishing Technology, Sunny adapted the technology for Asian skin tones and introduced it to Taiwan in 2021. Since then, she has demonstrated its effectiveness in over 1,000 successful cases. She holds certifications from Europe’s top embroidery academy, LipsArtis, and is a PHI Switzerland TATTOO Artist. Additionally, she serves as a lecturer for COSA International Semi-Permanent Review in Taiwan.

“More women today prioritize self-care, and intimate area skincare is not about pleasing others, it’s about feeling confident in our own skin. We are excited to introduce USFT Color Nourishing Technology, a solution that goes beyond traditional tattooing to deliver a natural and lasting transformation for women around the world.” Sunny said.

To better serve clients in Thailand, FT. Brahmā Aesthetics is in the process of recruiting local instructors to expand access to its innovative treatments.

About FT. Brahmā Aesthetics

FT. Brahmā Aesthetics specializes in non-invasive semi-permanent makeup and skin brightening solutions tailored to Asian skin tones. With agent students across multiple countries and regions, including Taiwan, Hong Kong, Malaysia, South Korea, Japan, Shanghai, the U.S., Canada, and Australia, these trained professionals act as local product and technology agents. The company also has lecturers in Hong Kong, Taiwan, and the U.S. The color-nourishing technology, developed in the U.S. in 2019 and introduced to Taiwan in 2021, has been successfully applied in over a thousand cases.

For more information, visit:

Website: https://master-sunny.com/

Instagram: https://www.instagram.com/ft.brahma.1986/

Neopets Powers Up Its Comeback: Strategic Partnership with Evolution to Boost Global Licensing Efforts

LOS ANGELES, April 2, 2025 /PRNewswire/ — Neopets (www.neopets.com), the beloved virtual pet game, is thrilled to announce a new partnership with Evolution, a leading US based licensing agency. This strategic move, effective April 2025, aims to enhance brand relevance and drive licensing growth. Together, they seek to strengthen Neopets’ presence in the global entertainment and gaming landscape by forging high-profile collaborations and expanding into new product categories and markets.

Neopets announces the partnership with Evolution to expand its global licensing opportunities.
Neopets announces the partnership with Evolution to expand its global licensing opportunities.

The announcement follows a record-breaking year in 2024, during which Neopets experienced a threefold increase in its player base, with daily active users (DAU) peaking at nearly 250,000 and monthly active users (MAU) surpassing 400,000 – the highest in the past decade. The brand also collaborated with over 30 partners to extend its reach across multiple categories. Notable successes include:

  • Neopets x Monopoly 25th Anniversary Edition: The limited collectible deluxe edition launch saw overwhelming demand, with all sets selling out within 24 hours. To meet the excitement from fans and collectors, a standard edition is already in the works, ensuring more players can experience this special collaboration.
  • Neopets x Upper Deck Trading Card Game (TCG): The launch of the Neopets Battledome TCG became an instant fan favourite, with booster packs and expansions in development to captivate players and collectors alike.
  • PhatMojo Blind Box Plushies: Neopets introduced its first plush line in over a decade, featuring characters like Aisha, Shoyru, Kacheek and more. These plushies have been a hit in major retailers such as Hot Topic and GameStop, quickly selling out and prompting reorders.

“We are excited to partner with Evolution,” said Dominic Law, CEO of Neopets. “Their proven expertise in retail management, strategic brand monetization and licensee acquisitions will play a key role in our journey to revive one of the world’s most iconic gaming titles. This collaboration will allow us to expand into new product categories and explore exciting opportunities with major brands across various fields.”

“Our goal is to help Neopets navigate today’s evolving licensing landscape and unlock new opportunities for brand growth across multiple product verticals,” stated Travis J. Rutherford, Co-Founder and Chief Revenue Officer at Evolution. “We are dedicated to creating innovative programs that not only celebrates Neopets’ rich legacy but also introduce fresh experiences that engage both longtime fans and new audiences.”

This partnership represents an important step in expanding Neopets’ reach through high-quality licensed products. With a focus on the U.S. and Canadian markets, Neopets aims to establish itself as a growing presence in the global licensing landscape. In 2025, fans can look forward to exciting new collaborations that will bring the magic of Neopia to life in delightful ways, allowing both nostalgic players and new audiences to engage with the brand like never before.

– END –

About Neopets

Loved by 150 million players worldwide, Neopets is the world’s favourite virtual pet game allowing players to create, care for and raise a wide range of innovative characters in the land of Neopia. Originally browser-based, today players can interact with Neopets across mobile devices and in real life through board games, plushie and trading cards. Under new leadership since July 2023, Neopets has reinvented itself, introducing 100+ classic mini-games, new storylines and licensing partnerships. These partnerships included collectibles, merchandise and tabletop gaming, Neopets blends digital and physical gaming engagement whilst living by core values of creativity and community. Now celebrating its 25th anniversary, Neopets continues to evolve as an inclusive entertainment brand that connects generations of players through shared Neopia adventures.

About Evolution

Evolution is a leading licensing and brand management agency headquartered in Calabasas, California, servicing the popular culture, television and film, gaming, toy, celebrity, character, outdoor, motorsports and lifestyle industry verticals. Evolution offers bespoke turn-key solutions, including strategic brand planning, market analysis, contract negotiations, legal support, product development, retail development, finance and royalty collections, contract compliance, inventor relations, as well as providing leading manufacturers a full service licensing acquisitions team.

Evolution monetizes and enhances brand value via licensing, direct to retail partnerships, collaborations, experiential retail, direct to consumer sales and location based entertainment.

The agency’s clients include: Gaumont Television, Stampede Ventures, Patricia Nash, Black Angus Steakhouse, Senna Brands, The Revelyst Group, Pressman Films, Morgan Creek Entertainment, Revolution Studios, Smoko, Tilting Point, OLO Industries, World of Neopets, and The Ella Fitzgerald Charitable Foundation, among others.

Bonnell Electric Unleashes the 775 Series: The Future of Electric Performance is Here

AUSTIN, Texas, April 1, 2025 /PRNewswire/ — Bonnell Electric is shaking up the e-MTB and e-moto landscape with the official launch of the 775 series. A revolutionary blend of power, precision, and adaptability, the 775 lineup is designed to push boundaries, offering three distinct ways to ride—whether it’s an all-access adventure commuter, a trail-busting MTB, or a category-defying fusion of mountain bike and dirt bike. And this is just the beginning—later this year, Bonnell’s first e-moto lineup will take electric performance even further into uncharted territory.


Meet Bonnell.

 

Meet Bonnell. Adventure-ready power and performance perfectly tuned to you.
Meet Bonnell. Adventure-ready power and performance perfectly tuned to you.

ADVENTURE-READY POWER AND PERFORMANCE PERFECTLY TUNED TO YOU

Bonnell is on a mission to bring adventure within reach. Every bike is a testament to the brand’s relentless pursuit of quality, precision, and customization—delivering the tools riders need to elevate their experience and make every journey unforgettable. The most epic rides only happen when everything works as one—technology, design, and service—all perfectly in sync no matter how you get your thrills.

Meet Bonnell – YouTube

“A DREAM COME TO LIFE”

“Bonnell is a dream come to life,” says Matthew Wauters, CEO and Founder. “Born from a small team of passionate riders and outdoor enthusiasts, we set out to build something we couldn’t find on the market. Every product is crafted with the rider in mind, optimized through countless hours of design, riding, and fine-tuning to adapt to your unique needs. The 775 series is our first expression of this vision. With a versatile frame, it seamlessly adapts to every part of your life—from grocery runs with the Touring kit to trail exploration with the AM, to off-road adventures with the MX.”

BUILT FOR EVERY THRILL | 775 SERIES

One platform, three ways to ride.

775 MX | NOT MTB. NOT MOTO. A NEW BREED.

Retail From:                 $5,495 USD

Intended Use:               Off-Road
Top Speed:                   40mph (65 km/h)
Peak Power:                 6000 Watts
Range:                          12–37miles (20-60 km)
Travel:                           200mm/170mm

Dual Crown Fork
Chromoly Front Triangle
Mullet Wheelset

The 775 MX is built for riders who refuse to be confined to one category. A hybrid between a downhill MTB and a lightweight dirt bike, it delivers the agility of a mountain bike with the raw power of a moto.

At just 75 lbs (34kg), this off-road machine is engineered for pure performance. The Lekkie Pacemaker Twist Throttle provides enhanced comfort and control, while the 775 MX delivers up to 6,000W of peak power and 280 Nm of peak torque for smooth, responsive acceleration. The 65V, 1300Wh battery supports long rides, charges in under four hours, and features dual-layer safety protection with Samsung 50s cells for durability and efficiency.

Designed to conquer rugged terrain, the 775 MX boasts a reinforced 4130 chromoly front triangle with anti-rust coating, paired with 6061 forged aluminum chainstays for superior durability. The Suntour Rux 38 RC+ fork and TriAir 3CR shock provide 200mm of front travel and 170mm of rear travel, ensuring smooth handling on steep descents, technical trails, and aggressive terrain. Magura MT5 brakes with MDR-P floating rotors deliver precise, high-performance stopping power.

775 AM | THE ALL-ACCESS PASS TO ADVENTURE

Retail From:                 $4,295 USD

Intended Use:              All-Mountain, Enduro
Top Speed:                  20-28mph (32-45 km/h)
Range:                         20-45miles (30-70 km)
Travel:                         160mm/150mm

Adjustable Geometry
Removable Battery/Crankset
Mullet Wheelset

The 775 AM isn’t just a bike—it’s a shape-shifter. Built for every kind of rider—from first-timers to full-on trail junkies—it combines modern geometry with a modular design and progressive suspension to handle any terrain you throw at it. With adjustable power and assist settings, you can fine-tune your ride for everything from cross-country exploration to gravity-fuelled bike park laps. Need to adapt on the fly? Easily toggle the throttle on or off to stay compliant with Class 2 and Class 3 regulations, or switch between e-bike mode and a traditional ride with a quick battery or crank swap.

For purists, the 775 AM is designed for flexibility: the battery and motor can be easily removed, converting it into a traditional MTB for a raw, pedal-powered experience. This seamless switchability ensures riders get the best of both worlds.

Bonnell 775 MX | A New Breed
Bonnell 775 MX | A New Breed

Bonnell 775 AM | All-Access Adventure
Bonnell 775 AM | All-Access Adventure

775 AM TOURING | COMMUTE. CONNECT. DISCOVER.

For riders seeking urban versatility, the Touring Package transforms the 775 AM into a fully equipped commuter in under 10 minutes. Designed for smooth commutes, quick errands, and weekend escapes, the 775 AM Touring is built for everyday adventure.

The Touring Kit includes waterproof bags, a 66lb (30kg) capacity rack, aluminum fenders, puncture-resistant Maxxis Metropass tires, and integrated Magic Shine lights—offering an effortless, reliable, and stylish way to move through the city.

Retail From:     $4,890 USD when purchased with 775 AM
                         $695 USD when sold individually

TAKE CONTROL: FULLY CUSTOMIZABLE PERFORMANCE

Bonnell’s e-MTB Ride Control App and Intuition Display provide advanced rider personalization—allowing 775 riders to fine-tune power modes, throttle response, and performance metrics while integrating Apple AirTag tracking for enhanced security. Designed for both professionals and everyday riders, it puts complete control at your fingertips.

NEXT-GEN ELECTRIC DIRT BIKES ON THE HORIZON

“With the 902 and 805, we’re scratching an itch riders didn’t even know they had—because they didn’t know bikes could do this. What you lose in the smell of gas and the roar of the engine, you more than make up for in the riding experience. From fully customizable ride modes to real-time performance data at your fingertips, these bikes don’t just react to you—they adapt to you. It’s a new level of control, precision, and connection to the ride that redefines what’s possible on two wheels.” says Wauters.

Bonnell 902 | Power. Precision. Pure Adrenaline.
Max Power:               46kW (62hp)
Battery Capacity:      6.6kWh Range Battery / 4.6kWh Race Battery (both swappable)
Wheels:                      21″ front / 18″ rear
Suspension:              285mm travel front and rear

The Bonnell 902 redefines what’s possible in electric dirt bikes. Packing 46kW (62hp) of power, over 900Nm of torque, and 285mm of suspension travel, the 902 is agile, powerful, and ultra-responsive. Whether you’re pushing the limits on the track or tackling rugged trails, it delivers unmatched precision and excitement.

Bonnell 805 | Next-Level Fun
Max Power:               30kW (40hp)
Battery Capacity:      3.1kWh Battery (swappable)
Wheels:                      21″ front / 18″ rear
Suspension:              245mm travel front and rear

The Bonnell 805 is a groundbreaking lightweight electric dirt bike, delivering 30kW (40hp) of power in a race-proven chassis. Outfitted with premium suspension, full-size 21/18 wheels, powerful brakes, and a modular battery system, the 805 is ready—no upgrades needed. Built for riders who demand versatility and peak performance, the 805 promises top-tier handling and adaptability.

ABOUT BONNELL

Bonnell is a global brand driven by a passion for two wheels and adventure. With teams in Austin, Perth, Hong Kong, and Dongguan, Bonnell blends innovative engineering with a deep commitment to the rider experience. Every bike is purpose-built for seamless performance, precision tunability, accessible power, and an authentic ride feel.

JOIN THE BONNELL COMMUNITY

Bonnell invites riders of all levels to be part of the next generation of two-wheel adventure.
For more information, visit https://ridebonnell.com/ or follow us on Instagram @ridebonnell.

Bonnell 775 AM Touring | Commute. Connect. Discover.
Bonnell 775 AM Touring | Commute. Connect. Discover.

Bonnell e-Motos | Silence has never made so much noise.
Bonnell e-Motos | Silence has never made so much noise.

 

Annual General Meeting of AB SKF

GOTHENBURG, Sweden, April 1, 2025 /PRNewswire/ — The Annual General Meeting of Aktiebolaget SKF was held on Tuesday, 1 April 2025.

The income statements and the balance sheets were adopted, together with the Board’s proposal for distribution of dividend. A dividend of SEK 7.75 per share was approved. To be entitled to receive the dividend, shareholders must be recorded in the share register on Thursday, 3 April 2025.

The Board members and the CEO were discharged from liability for their administration of the company for the financial year 2024.

Hans Stråberg, Hock Goh, Geert Follens, Håkan Buskhe, Susanna Schneeberger, Rickard Gustafson, Beth Ferreira, Therese Friberg, Richard Nilsson and Niko Pakalén were reelected as Board members. Mats Rahmström was newly elected as a Board member.

Hans Stråberg was elected Chair of the Board. The Board has appointed Håkan Buskhe and Mats Rahmström as Vice Chairs of the Board. The Board has also decided to establish two Board Committees; an Audit and Sustainability Committee as well as a People Committee.

The Annual General Meeting resolved that the Board fee for 2025 shall be:

a.  SEK 3,025,000 to the Chair of the Board of Directors,

     SEK 1,515,000 to the Vice Chair(s) of the Board of Directors, and

     SEK 990,000 to each of the other Board members; and

           

b.  SEK 385,000 to the Chair of the Audit Committee,

     SEK 275,000 to each of the other members of the Audit Committee,

     SEK 220,000 to each of the Chairs of the other Committees, and

     SEK 165,000 to each of the other members of the other Committees;

30 percent of the Board fee (excluding the Committee fees) should be converted and consist of a variable Board fee (so-called synthetic shares). Complete terms for the variable Board fee (synthetic shares) are available on www.skf.com among the Board’s compete proposals.

A special meeting fee of EUR 2,000 for travel within Europe and EUR 5,000 for intercontinental travel to a physical Board meeting in Sweden shall be paid to Board members residing outside of Sweden, and to Board members residing in Sweden for travel to a physical Board meeting outside of Sweden.

A prerequisite for obtaining remuneration is that the Board member is elected by the General Meeting and is not employed by the company.

The Annual General Meeting approved the Board’s proposal to amend the Articles of Association to foremost adjust the term of office for the appointed auditor. Deloitte AB was elected auditor of the company for a period of one year until the end of the annual general meeting held during 2026.

The Annual General Meeting approved the Board’s remuneration report and the Board’s proposal for a resolution on SKF’s Performance Share Programme 2025. The programme is proposed to cover senior managers and key employees in the SKF Group with an opportunity to be allotted, free of charge, SKF B shares. Under the programme, not more than in total 1,000,000 SKF B shares may be allotted. The allotment of shares shall be related to the level of achievement of the Total Value Added (TVA) target, as defined by the Board, and the SKF Group’s CDP Climate Change score performance measure during the three-year programme period. The programme does not entail any dilution of the company’s shares. The principal terms and guidelines of the programme can be found in the Board’s proposal at www.skf.com.

Aktiebolaget SKF
      (publ)

For further information, please contact:

Press Relations: Carl Bjernstam, +46 31-337 2517; +46 722 201 893; carl.bjernstam@skf.com
Investor Relations: Sophie Arnius, +46 31-337 8072; +46 705 908072; sophie.arnius@skf.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/skf/r/annual-general-meeting-of-ab-skf,c4128549

The following files are available for download: